12:00 pm - 2:00 pm
Edmonton Clinic Health Academy (ECHA), ECHA 1-490, Edmonton
AFNS 601: Seminar
Human Nutrition
Friday, February 28 , 2020
12:00 PM
Room: ECHA 1-490
Evaluating the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in combination with standard therapy for advanced non-small cell lung cancer: protocol of a phase II randomized controlled trial
Speaker 1: Pamela Klassen
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in Canada. Standard of care for advanced stage disease includes chemotherapy and/or immunotherapy. Supplementation with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been shown in pre-clinical and phase I studies to improve the efficacy of chemotherapy, maintain skeletal muscle mass and attenuate treatment toxicities in this population. Our primary objective is to investigate the effect of EPA and DHA supplementation on disease control rate in patients with advanced NSCLC undergoing standard treatment.
Innovative Approaches to the Lack of Evidence-Based Energy Requirements for Patients with Cancer
Speaker 2: Ana Paula Pagano
The majority of patients with cancer experience malnutrition. Malnutrition in cancer is primarily manifested by severe muscle depletion that occurs at any stage and often co-exists with obesity. The malnutrition-low muscle mass syndrome in cancer is associated with physical disability, extended hospitalization, infectious and non-infectious complications, increased risk for severe toxicity during cancer treatment and shortened survival. Characterizing energy metabolism is essential to understand energy requirements to ultimately modulate energy balance, optimizing weight, body composition and clinical outcomes during cancer trajectory. However, current nutrition guidelines for people with cancer are not specific and lack a sufficient evidence base. Our objective is to describe energy requirements in patients with stages II or III (curative) colorectal cancer (n = 36). In this longitudinal study, precise techniques and approaches (whole-body calorimetry unit, doubly labeled water and activity monitors) will be used to characterize energy metabolism changes throughout cancer treatment. Specifically, we will be investigating total energy expenditure, resting energy expenditure, and physical activity levels in a free-living setting. Body composition assessment (iDXA) will allow us to understand how energy requirements vary across different body composition types. We anticipate that our results will highlight the need for adjusting current nutritional guidelines and the need for incorporating contemporary bedside tools to guide nutrition therapy.
For further information, please contact Tracy Anstey tlanstey@ualberta.ca
Categories: